Merck KGaA v. Integra Lifesciences I, Ltd.

Global Cell Freezing Media Market to Reach $291.3 Million by 2030 - Driven by Rising Adoption of Ready-to-Use Freezing Media - ResearchAndMarkets.com

Retrieved on: 
Friday, September 15, 2023
Other Health, Research, Pharmaceutical, Technology, Genetics, Health Technology, Science, Biotechnology, Stem Cells, Other Technology, Other Science, Health, Vaccine, Biopharmaceutical, CRISPR, Partnership, Merck KGaA v. Integra Lifesciences I, Ltd., Prevalence, Cell, Biopreservation, COVID-19, Cancer, DSM-IV codes, USD, Disorder, Cryopreservation, Regenerative medicine, Traction, Investment, Sigma-Aldrich, Freezing, Genetic, Sanofi, Conditional sentence, DMSO, Safety, Mobile phone, Pharmaceutical industry, Fine chemical, Application, Glycerol

This report projects that the global cell freezing media market is set to achieve a remarkable milestone, with an expected valuation of USD 291.3 million by 2030.

Key Points: 
  • This report projects that the global cell freezing media market is set to achieve a remarkable milestone, with an expected valuation of USD 291.3 million by 2030.
  • Additionally, the prevalence of chronic disorders and the growing significance of cell therapies in their management have generated traction for effective cell freezing media.
  • Cell freezing media play a crucial role in preserving cell functionality during freezing and thawing processes, which is vital for cell therapy applications.
  • High Cost Associated with Cryopreservation and Cell Freezing Media: The cost implications of cryopreservation and cell freezing media pose a challenge to market growth.

Integra LifeSciences Reports Select Preliminary Fourth Quarter and Full-Year 2022 Financials

Retrieved on: 
Tuesday, January 10, 2023
Sale, Share repurchase, Conference, Merck KGaA v. Integra Lifesciences I, Ltd., Integra, Video game, Textile, Fine chemical, Pharmaceutical industry, Car rental

PRINCETON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2022 financial results.

Key Points: 
  • Fourth quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range.
  • Full-year quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range.
  • PRINCETON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, announced today certain unaudited preliminary fourth quarter and full-year 2022 financial results.
  • Fourth quarter 2022 adjusted earnings per diluted share is expected to be above the high end of the Company’s October guidance range.

EQS-News: Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

Retrieved on: 
Sunday, January 22, 2023
Electrophysiology, Merck KGaA v. Integra Lifesciences I, Ltd., Arrhythmia, Medtech, MD, Artificial intelligence, CFO, Temperature, Boston Scientific, Disease, JD, Patient, Integra, AF, Software, Physician, Heart, Catheter ablation, Lightstone, Atrial fibrillation, Medical device, Security (finance)

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

Key Points: 
  • Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced
    The issuer is solely responsible for the content of this announcement.
  • The funding round was led by U.S.-based Vensana Capital with co-investment from Lightstone Ventures and existing investor Gilde Healthcare .
  • The funding will help accelerate new product development, support additional clinical trials, prepare for full-scale US commercialization, and pursue further regulatory approvals.
  • We are confident that Volta’s innovative AI software will transform the effectiveness and efficiency of these challenging procedures.”
    Volta Medical also is pleased to announce the appointment of experienced medical device executive, John Slump, as CFO of Volta Medical.

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

Retrieved on: 
Thursday, January 5, 2023
Electrophysiology, Merck KGaA v. Integra Lifesciences I, Ltd., Arrhythmia, Medtech, MD, Artificial intelligence, CFO, Temperature, Boston Scientific, Disease, Patient, JD, Integra, AF, Physician, Heart, Catheter ablation, Lightstone, Atrial fibrillation, Medical device

The funding round was led by U.S.-based Vensana Capital with co-investment from Lightstone Ventures and existing investor Gilde Healthcare .

Key Points: 
  • The funding round was led by U.S.-based Vensana Capital with co-investment from Lightstone Ventures and existing investor Gilde Healthcare .
  • The funding will help accelerate new product development, support additional clinical trials, prepare for full-scale US commercialization, and pursue further regulatory approvals.
  • “There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF,” said Theophile Mohr Durdez, Volta Medical CEO and co-founder.
  • We are confident that Volta’s innovative AI software will transform the effectiveness and efficiency of these challenging procedures.”
    Volta Medical also is pleased to announce the appointment of experienced medical device executive, John Slump, as CFO of Volta Medical.

PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany

Retrieved on: 
Tuesday, January 3, 2023
Cancer, Standard of care, OS, International, Head, Food, Infection, Vulvar cancer, Merck, PDS, Platinum, Biotechnology, Neoplasm, Patient, Merck KGaA v. Integra Lifesciences I, Ltd., CPI-0610, PD-L1, FDA, Webcast, IL-12, Food and Drug Administration Amendments Act of 2007, Merck Group, Longevity, PDSB, National Cancer Institute, Neck, TGF, PARK, Palladium, Pharmaceutical industry, CPI

FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced an exclusive global license agreement with Merck KGaA, Darmstadt, Germany for the tumor-targeting IL-12 fusion protein M9241 (formerly known as NHS-IL12), which will join the pipeline as PDS0301. M9241 appears to enhance the proliferation, potency and longevity of T cells in the tumor. The combination of Versamune® and IL-12 is patented by PDS Biotech and is designed to overcome tumor immune suppression utilizing a different mechanism from checkpoint inhibitors.

Key Points: 
  • Under the terms of the agreement, PDS Biotech will receive from Merck KGaA, Darmstadt, Germany an exclusive license to M9241.
  • PDS Biotech will assume responsibility for future development, commercialization, and manufacturing of M9241.
  • “We are pleased to have partnered with Merck KGaA, Darmstadt, Germany to advance the development of M9241, a highly innovative cytokine therapy,” said Dr. Frank Bedu-Addo, PDS Biotech CEO.
  • “Under the licensing arrangement between Merck KGaA, Darmstadt, Germany and PDS Biotech, assumption of an equity stake by Merck KGaA, Darmstadt, Germany in PDS Biotech further confirms the potential of the Versamune® platform and the data generated to date with this combination therapy.

Surgical Sealants, Adhesives and Hemostats Global Market - Forecast to 2029

Retrieved on: 
Thursday, December 22, 2022
Merck KGaA v. Integra Lifesciences I, Ltd., Johnson & Johnson, General surgery, Gel, SAH, Adhesive, Ethicon Inc., Baxter International, Medtronic, Bleeding, Urology, Hospital, Health, Ageing, Infection, Geography, Fibrin, Speciality chemicals, Hemostasis, Orthopedic surgery, Pulmonology, Others, Gynaecology, Teleflex, CryoLife, Neurosurgery

View original content:https://www.prnewswire.com/news-releases/surgical-sealants-adhesives-and...

Key Points: 
  • According to IQ4I analysis, the SAH global market is expected to grow at mid-single digit CAGR from 2022 to 2029 to reach $4,366.0 million by 2029.
  • The SAH global market is mainly segmented based on products, applications, end-users, and based on geography.
  • Among these, the hemostat accounted for the largest revenue in 2022 and is expected to grow at mid-single digit CAGR from 2022 to 2029.
  • Hemostats are classified based on function into mechanical hemostats, active hemostats, flowable hemostats, and fibrin sealants hemostats, among them, the mechanical hemostats accounted for the largest revenue in 2022 and are expected to grow at mid-single digit CAGR from 2022 to 2029.

Integra LifeSciences Completes the Acquisition of Surgical Innovation Associates

Retrieved on: 
Tuesday, December 6, 2022
Acquisition, SIA, ICP, Annual report, Integra, Health, Security (finance), News, Merck KGaA v. Integra Lifesciences I, Ltd., Risk, TCC, Risk management

PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA).

Key Points: 
  • PRINCETON, N.J., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA).
  • For the latest news and information about Integra and its products, please visit integralife.com .
  • All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements.
  • Such forward-looking statements involve risks and uncertainties that could cause actual results to differ from predicted results.

Integra LifeSciences Announces Definitive Agreement to Acquire Surgical Innovation Associates (SIA) and Plans for $150 Million Share Repurchase

Retrieved on: 
Thursday, December 1, 2022
Growth, TCC, ICP, Sulfoxide, Merck KGaA v. Integra Lifesciences I, Ltd., Northwestern University, Safety, Acquisition, Health, Integra, BofA Securities, Annual report, Proskauer, PMA, Security (finance), News, Bank of America, Surgeon, Risk, Share repurchase, Woman, PRS, Breast cancer, Mastectomy, FDA, Medical imaging, Bank, Financial adviser, Risk management

PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it entered into a definitive agreement to acquire Surgical Innovation Associates (SIA), which develops, markets and sells DuraSorb®, a resorbable synthetic matrix for plastic and reconstructive surgery. This acquisition will advance Integra’s global strategy in breast reconstruction, expanding plans to access the U.S. market with devices specifically approved by the FDA for use in implant-based breast reconstruction (IBBR) procedures. The transaction is expected to close by the end of the year, subject to the satisfaction of customary conditions.

Key Points: 
  • The addition of DuraSorbs resorbable synthetic technology will further strengthen Integras plastic and reconstructive surgery portfolio, which includes SurgiMend PRS , a xenograft surgical matrix.
  • The global breast reconstruction market represents an attractive growth opportunity for our surgical reconstruction business, said Robert T. Davis, Jr., executive vice president and president, Tissue Technologies, Integra LifeSciences.
  • The company is planning a $150 million share repurchase as a part of a previous approval by the board of directors.
  • Surgical Innovation Associates, Inc (SIA) is a Northwestern University spin-out founded in 2016 by Alexei Mlodinow, Todd Cruikshank, and technology inventor Dr. John Kim.

Surgical Innovation Associates (SIA) Announces Definitive Agreement to be Acquired by Integra LifeSciences

Retrieved on: 
Thursday, December 1, 2022
Research, General Health, Oncology, Medical Devices, Other Manufacturing, Science, Surgery, Chemicals, Plastics, Biotechnology, Medical Supplies, Manufacturing, Health, Warning, Growth, TCC, Weakness, Use, ICP, Sulfoxide, Merck KGaA v. Integra Lifesciences I, Ltd., Northwestern University, Ideation, Acquisition, Health, Physician, Patient, Integra, BofA Securities, Proskauer, Federal Food, Drug, and Cosmetic Act, PMA, News, Bank of America, Surgeon, CE, Entrepreneurship, Mastectomy, PRS, FDA, Health insurance, Medical device, Medical imaging, EU

Surgical Innovation Associates (SIA) today announced that it entered into a definitive agreement to be acquired by Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company.

Key Points: 
  • Surgical Innovation Associates (SIA) today announced that it entered into a definitive agreement to be acquired by Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company.
  • The transaction is expected to close by the end of the year, subject to the satisfaction of customary conditions.
  • Today, there are no surgical matrices approved by the FDA specifically for use in implant-based breast reconstruction (IBBR) for mastectomy patients.
  • Integra is the only manufacturer so far to submit a premarket approval (PMA) application for this soft tissue support in IBBR.

TILT Biotherapeutics Announces Boston Office Opening as it Expands its Clinical Trials in the US

Retrieved on: 
Wednesday, November 9, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, MSD, European Innovation Council, Merck KGaA v. Integra Lifesciences I, Ltd., Head, TIL, IND, CAR, Tumor microenvironment, Partnership, Cytokine, Merck, University of Helsinki, Mayo Clinic, Large-cell lung carcinoma, Merck & Co., Potyvirus, PD-L1, Clinical professor, TILT, II, Cancer, CIC, Program, University, Ovarian cancer, Patient, Heart, Therapy, Business Finland, Pharmaceutical industry, Vaccine

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities.

Key Points: 
  • TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the company has opened an office in Boston, to support its increasing US clinical development, partnering and fund-raising activities.
  • The current US clinical trials are run in collaboration with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA and the Merck-Pfizer-Alliance.
  • TILT Biotherapeutics LLCs new office is at the CIC in Boston, Massachusetts which has been a home for great entrepreneurs leading fast-growing companies since 1999.
  • TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo, and it is currently in Phase I clinical trials.